HC Wainwright Has Positive Forecast for CRDF Q1 Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of Cardiff Oncology in a research report issued on Wednesday, February 25th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.12) for the quarter, up from their prior forecast of ($0.16). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Cardiff Oncology’s Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.49) EPS.

Other research analysts have also issued reports about the company. Piper Sandler decreased their price objective on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday. Noble Financial assumed coverage on shares of Cardiff Oncology in a research report on Monday, January 5th. They set an “outperform” rating and a $12.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cardiff Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.10.

Cardiff Oncology Stock Performance

Shares of NASDAQ:CRDF opened at $1.94 on Friday. The business has a fifty day moving average of $2.32 and a 200-day moving average of $2.25. Cardiff Oncology has a twelve month low of $1.48 and a twelve month high of $4.56. The firm has a market cap of $132.62 million, a PE ratio of -2.81 and a beta of 1.33.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07. Cardiff Oncology had a negative net margin of 7,733.22% and a negative return on equity of 82.01%. The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.13 million.

Hedge Funds Weigh In On Cardiff Oncology

Several hedge funds have recently modified their holdings of CRDF. Virtu Financial LLC bought a new position in Cardiff Oncology during the fourth quarter worth $108,000. XTX Topco Ltd boosted its holdings in Cardiff Oncology by 40.5% in the 4th quarter. XTX Topco Ltd now owns 219,357 shares of the company’s stock valued at $616,000 after purchasing an additional 63,196 shares during the period. Millennium Management LLC grew its position in shares of Cardiff Oncology by 441.5% during the 4th quarter. Millennium Management LLC now owns 194,420 shares of the company’s stock worth $546,000 after purchasing an additional 158,519 shares in the last quarter. Laurion Capital Management LP increased its stake in Cardiff Oncology by 7.3% during the 4th quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock worth $7,437,000 after acquiring an additional 180,866 shares during the period. Finally, Tamar Securities LLC acquired a new stake in shares of Cardiff Oncology during the 4th quarter worth $32,000. Institutional investors own 16.29% of the company’s stock.

Cardiff Oncology News Summary

Here are the key news stories impacting Cardiff Oncology this week:

• Positive Sentiment: HC Wainwright raised quarterly and full‑year EPS forecasts and reiterated a Buy rating with a $10 price target — the firm increased Q1–Q4 2026 and FY2026 EPS estimates (FY now -$0.49 versus prior -$0.64), reflecting a less‑negative earnings outlook that can support upside. HC Wainwright research notes / MarketBeat
• Positive Sentiment: Company announced management will participate in three investor conferences in March — added investor access and upcoming presentations can improve visibility and drive short‑term buying interest. Cardiff Oncology to Participate in Three Upcoming Investor Conferences
• Neutral Sentiment: Coverage pieces and news summaries (e.g., AAII) reported a prior intraday rally (~+10%) that appears linked to the HC Wainwright chatter and conference news — media attention can amplify short‑term volatility but doesn’t change fundamentals by itself. Why Cardiff Oncology’s (CRDF) Stock Is Up 10.01%
• Negative Sentiment: Piper Sandler cut its price target to $6.00 — a lower target from another sell‑side firm increases mixed messaging and can weigh on sentiment, limiting upside from the HC Wainwright call. Piper Sandler Lowers Cardiff Oncology Price Target to $6.00
• Neutral Sentiment: Reported short‑interest data in the filings is effectively meaningless/noisy (shows 0 shares and NaN changes) — no clear short squeeze signal from the published short interest. (Likely not a material factor until reliable short‑interest figures appear.)

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.